Biogen's Alzheimer's trial data ignites excitement and uncertainty over tau-targeting therapies

Biogen recently shared results from a late-stage Alzheimer's trial that tested a therapy aimed at the tau protein, a key hallmark of the disease.

The findings have sparked enthusiasm among researchers and investors who see the data as a potential step forward for tau-targeting strategies.

At the same time, many experts expressed confusion, noting that the results were mixed and left unanswered questions about the drug's efficacy and future development.